Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06977451

Personalized Antisense Oligonucleotide for a Single Participant With CHCHD10 ALS

This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single participant with amyotrophic lateral sclerosis (ALS) due to a pathogenic variant in CHCHD10

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Conditions

Amyotrophic Lateral Sclerosis Central Nervous System Diseases Metabolic Diseases Motor Neuron Disease Nervous System Diseases Neurodegenerative Diseases Neuromuscular Diseases Nutritional and Metabolic Diseases Proteostasis Deficiencies Spinal Cord Diseases TDP-43 Proteinopathies

Age range

63 year–63 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

Columbia University, Irving Medical Center

New York, 10032, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Informed consent/assent provided by the participant (when appropriate), and/or participant's parent(s) or legally authorized representative(s).
  • Ability to travel to the study stie and adhere to study-related follow-up examinations and/or procedures and provide access to participant's medical records.
  • Genetically confirmed neurological disorder.

Exclusion criteria

  • Participant has any condition that in the opinion of the Site Investigator, would ultimately prevent the completion of study procedures.
  • Use of an investigational medication within less than 5 half-lives of the drug at enrollment

Treatment and study plan

nL-CHCHD-001

Drug

Personalized Antisense Oligonucleotide

Primary outcomes

  1. Clinical Functioning

    Time frame: Baseline to 12 months

    Change from baseline at 12-months post nL-CHCHD-001 administration in scores on Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R). A maximum score of 48 represents normal functioning, and the minimum score is 0.

  2. Motor Functioning

    Time frame: Baseline to 12 months

    Change from baseline at 12-months post nL-CHCHD-001 administration in scores on Slow Vital Capacity (SVC) Performance.

  3. Motor Functioning

    Time frame: Baseline to 12 months

    Change from baseline at 12-months post nL-CHCHD-001 administration in scores on Handheld Dynamometry (HHD).

  4. Clinical Functioning

    Time frame: Baseline to 12 months

    Change from baseline at 12-months post nL-CHCHD-001 administration in scores on Edinburgh Cognitive and Behavioral ALS Screen (ECAS).

  5. Clinical Functioning

    Time frame: Baseline to 12 months

    Change from baseline at 12-months post nL-CHCHD-001 administration in scores on ALS Cognitive Behavioral Screen (ALS-CBS)

  6. Clinical Functioning

    Time frame: Baseline to 12 months

    Change from baseline at 12-months post nL-CHCHD-001 administration in scores on Amyotrophic Lateral Sclerosis Assessment Questionnaire 5 (ALSAQ-5)

Secondary outcomes

  1. Disease Biomarkers

    Time frame: Baseline to 12 months

    Change from baseline at 12-months post nL-CHCHD-001 administration in serum and cerebrospinal fluid neurofilament light chain levels

  2. Safety and Tolerability

    Time frame: Baseline to 12 months

    Incidence and Severity of Adverse Events

  3. Safety and Tolerability

    Time frame: Baseline to 12 months

    Emergent abnormalities in physical exam

  4. Safety and Efficacy

    Time frame: Baseline to 12 months

    Emergent abnormalities in neurological exam

  5. Safety and Efficacy

    Time frame: Baseline to 12 months

    Emergent abnormalities in safety labs (CSF, chemistry, hematology, coagulation, and urinalysis)

Sponsors and collaborators

Lead sponsor

n-Lorem Foundation

Other

Collaborators

  • Columbia University

Registry information

Official study title

An Open-Label Single Center, Single Participant Study of an Experimental Antisense Oligonucleotide Treatment for Amyotrophic Lateral Sclerosis (ALS) Due to an Arg15Leu Pathogenic Variant in CHCHD10

Important dates

Study start
2024
Primary completion
2027
Study completion
2027
First posted
May 18, 2025
Registry last updated
Jul 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.